WAVE Life Sciences end PRECISION-HD1 and HD2 trials
It saddens us to bring you more unfortunate news on the Huntington’s disease trial front. WAVE Life Sciences have ended their PRECISION-HD1 and HD2 trials, discontinuing the production of WVE-120101 and WVE-120102.
Why have the trials ended?
Results from the PRECISION-HD2 trial showed no significant change in the huntingtin protein in adults with Huntington’s disease who were treated with WVE-120102 relative to those treated with a placebo. WVE-120102 was generally safe and well tolerated at lower doses; however, there were safety events experienced at the highest dose which led to participants discontinuing the trial.
Similarly, the results of the PRECISION-HD1 trial showed no significant change in the huntingtin protein in adults with Huntington’s treated with WVE-120101 relative to those treated with placebo.
Participants who are currently enrolled on the trial will have a final follow up visit, but will not receive any further doses.
What now?
WAVE continues to carry out research in Huntington's disease, with a third Huntington’s disease clinical candidate, WVE-003. This is a selective ASO (antisense oligonucleotide) that is designed to reduce the mutant huntingtin, whilst leaving the healthy protein unchanged.
“The promising preclinical data we have seen thus far with WVE-003 give us confidence in this novel program.” - Wave Life Sciences
This trial is expected to start in 2021.
HDBuzz have released an article on the trial with further information. Take a look here.
Whilst today's news is not what the community would like to hear, there is still a lot to be hopeful about.
If you are affected by Huntington’s disease and need support or advice, please contact us on 0151 331 5444 or email [email protected].
It saddens us to bring you more unfortunate news on the Huntington’s disease trial front. WAVE Life Sciences have ended their PRECISION-HD1 and HD2 trials, discontinuing the production of WVE-120101 and WVE-120102.
Why have the trials ended?
Results from the PRECISION-HD2 trial showed no significant change in the huntingtin protein in adults with Huntington’s disease who were treated with WVE-120102 relative to those treated with a placebo. WVE-120102 was generally safe and well tolerated at lower doses; however, there were safety events experienced at the highest dose which led to participants discontinuing the trial.
Similarly, the results of the PRECISION-HD1 trial showed no significant change in the huntingtin protein in adults with Huntington’s treated with WVE-120101 relative to those treated with placebo.
Participants who are currently enrolled on the trial will have a final follow up visit, but will not receive any further doses.
What now?
WAVE continues to carry out research in Huntington's disease, with a third Huntington’s disease clinical candidate, WVE-003. This is a selective ASO (antisense oligonucleotide) that is designed to reduce the mutant huntingtin, whilst leaving the healthy protein unchanged.
“The promising preclinical data we have seen thus far with WVE-003 give us confidence in this novel program.” - Wave Life Sciences
This trial is expected to start in 2021.
HDBuzz have released an article on the trial with further information. Take a look here.
Whilst today's news is not what the community would like to hear, there is still a lot to be hopeful about.
If you are affected by Huntington’s disease and need support or advice, please contact us on 0151 331 5444 or email [email protected].